Neuroblastoma Pipeline Assessment, Key Companies, And Emerging Drugs

 Breaking News
  • No posts were found

Neuroblastoma Pipeline Assessment, Key Companies, And Emerging Drugs

February 27
00:29 2021
Neuroblastoma Pipeline Assessment, Key Companies, And Emerging Drugs

Delveinsight Business Research LLP

“Neuroblastoma Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Neuroblastoma Market.

The Neuroblastoma Pipeline report embraces in-depth commercial and clinical assessment of the Neuroblastoma pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuroblastoma collaborations, licensing, mergers, and acquisition, funding, designations, and other product-related details.

Get FREE sample copy at

Neuroblastoma Pipeline Analysis
Companies across the globe are thoroughly working towards the development of new treatment therapies for Neuroblastoma. Some of the companies have recently shifted their focus towards this indication, which is expected to create a significant influence on the Neuroblastoma market size in the upcoming years.

Neuroblastoma companies:
Y-mabs therapeutics
Clarity Pharmaceuticals
Autolus Therapeutics
United Therapeutics Corp
EUSA Pharma
And many others

Neuroblastoma therapies covered in the report include:
And many more.

Neuroblastoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Neuroblastoma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Neuroblastoma treatment.

  • Neuroblastoma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Neuroblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Neuroblastoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Scope of the report

  • The Neuroblastoma Pipeline Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neuroblastoma across the complete product development cycle, including all clinical and non-clinical stages.

  • It comprises detailed profiles of Neuroblastoma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

  • Detailed research and development progress and clinical trial of Neuroblastoma, results wherever available, are also included in the pipeline study.

  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Neuroblastoma. 

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Neuroblastoma.    

  • In the coming years, the Neuroblastoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence Neuroblastoma Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the Neuroblastoma treatment market. Several potential therapies for Neuroblastoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Neuroblastoma market size in the coming years.  

  • Our in-depth analysis of the Neuroblastoma pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of Content

1. Report Introduction

2. Neuroblastoma 

3. Neuroblastoma Current Treatment Patterns

4. Neuroblastoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Neuroblastoma Late Stage Products (Phase-III)

7. Neuroblastoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Neuroblastoma Discontinued Products

13. Neuroblastoma Product Profiles

14. Neuroblastoma Key Companies

15. Neuroblastoma Key Products

16. Dormant and Discontinued Products

17. Neuroblastoma Unmet Needs

18. Neuroblastoma Future Perspectives

19. Neuroblastoma Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Related Reports
Neuroblastoma Market Insight
DelveInsight’ s Neuroblastoma – Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology in the 7MM as well as the market trends. 

Neuroblastoma Epidemiology Forecast 
DelveInsight’s Neuroblastoma – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Neuroblastoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Latest BioPharma Blogs – Hypofibrinogenemia Therapeutics Market

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States